butabarbital decreases outcomes of sufentanil SL by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Intently. Coadministration of CYP3A4 inducers may well reduce sufentanil levels and efficacy, maybe precipitating withdrawal syndrome in sufferers who may have formulated physical dependence to sufentanil. Discontinuatio